TESARO secures $500 million non-dilutive term loan financing
TESARO announced it has entered into a definitive term loan agreement with BIOPHARMA CREDIT and BIOPHARMA CREDIT INVESTMENTS IV, investment funds managed by Pharmakon Advisors. The loan facility provides TESARO with up to $500 million of borrowing capacity available in two tranches. November 21, 2017